European Commission does U-turn on human tissue regulation
This article was originally published in Clinica
Tissue-engineered products containing non-viable human tissues and cells may now be excluded from the long-awaited human tissue-engineered product Regulation being drafted by the European Commission's Directorate General Enterprise. Industry learnt of the surprise turnaround during a meeting with the Commission on June 23, Shayesteh Furst-Ladani, chair of the cell and tissues working group at industry association EuropaBio, told the 12th annual ABHI/IBC Global Conferences meeting on Medical Device Regulation, on June 24.
You may also be interested in...
A recent segment of CBS News “60 Minutes” discussing potential health benefits from probiotics was highly criticized by groups including the Consumer Healthcare Products Association, the Council for Responsible Nutrition, the Natural Products Association and the International Probiotics Association.
After a 12-month period that has seen Stada make significant investments in generics, biosimilars and consumer healthcare, CEO Peter Goldschmidt tells Generics Bulletin that the firm does not intend to stop there, as it pursues both organic and inorganic growth opportunities.
Samsung Bioepis is the latest company to stare down a lawsuit from Genentech over Avastin patents in the US. The Korean firm is aiming to be amongst the early biosimilar movers, after the market formed a year ago.